1. Why are private companies, small bio-tech pharmaceutical companies, and companies in a brand new super growth sector (i.e. social media or the internet 15 years ago) harder to value?

2. Discuss the valuation techniques that could be used for younger, growth companies and why these approaches are usually much more subjective than older established companies with solid earnings.